Evaluation of the efficiency and safety of lipid-lowering therapy in comorbid patients
- Authors: Shishkova V.1, Remennik A.1, Zotova L.1, Zotova E.1
-
Affiliations:
- Center for Speech Pathology and Neurorehabilitation
- Issue: Vol 29, No 4 (2018)
- Pages: 54-58
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/117196
- DOI: https://doi.org/10.29296/25877305-2018-04-10
- ID: 117196
Cite item
Open Access
Access granted
Abstract
The efficacy and safety of pitavastatin at doses of 2 and 4 mg daily and rosuvastatin at a dose of 10 mg daily were investigated in comorbid patients with first-time ischemic stroke.
Full Text
About the authors
V. Shishkova
Center for Speech Pathology and Neurorehabilitation
Email: veronika-1306@mail.ru
Candidate of Medical Sciences
A. Remennik
Center for Speech Pathology and NeurorehabilitationCandidate of Medical Sciences
L. Zotova
Center for Speech Pathology and Neurorehabilitation
E. Zotova
Center for Speech Pathology and Neurorehabilitation
References
- Шальнова С.А., Деев А.Д. Тенденции смертности в России в начале XXI века (по данным официальной статистики) // Кардиоваск. тер. и профилакт. -2011; 10 (6): 5-10.
- Оганов Р.Г., Масленникова Г.Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения // Кардиоваск. тер. и профилакт. - 2012; 11 (2): 5-10.
- Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016 // Рос. кардиол. журн. - 2017; 5 (145): 7-77.
- Barylski M., Nikolic D., Banach M. et al. Statins and New-Onset Diabetes // Current Pharmaceutical Design. - 2013; 19: 1-8.
- Sattar N., Preiss D., Murray H. et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials // Lancet. - 2010; 375: 735-42.
- Ishikawa M., Okajima F., Inoue N. et al. Distinct effects of pravastatin, atorvastatin and simvastatin on insulin secretion from a beta-cell line, MIN6 cells // J. Atheroscler. Thromb. - 2006; 13 (6): 329-35.
- Yamakasava T., Takano T., Tanaka S. et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus // J. Atheroscler. Thromb. - 2008; 15: 269-75.
- Boyd C. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for performance // JAMA. - 2005; 294 (6): 716-24.
- Шишкова В.Н. Коморбидность и полипрагмазия // Врач. - 2017; 7: 26-30.
- Mukhtar R., Reid J., Reckless J. Pitavastatin // Int. J. Clin. Pract. - 2005; 59: 239-52.
- Weng T., Yang Y., Lin S. et al. A systematic review and meta-analysis on the therapeutic equivalence of statins // J. Clin. Pharm. Ther. - 2010; 35: 139-51.
- da Silva P. Are all statins the same?: Focus on the efficacy and tolerability of pitavastatin // Am. J. Cardiovasc. Drug. - 2011; 11: 93-107.
- Corsini A., Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins ’Achilles’ heel? // Curr. Med. Res. Opin. - 2011; 27: 1551-62.
- Kurihara Y., Douzono T., Kawakita K. et al. A large-scale, long-term, prospective postmarketing surveillance olpitavastatin (LIVALO® Tablet) - LIVALO Effectiveness and Safety (LIVES) Study // Jpn. Pharmacol. Ther. - 2008; 36: 709-31.
- Шишкова В.Н., Капустина Л.А. Проблемы коморбидного пациента: как выбрать правильный статин // Фармакотерапия. - 2017; 17: 14-23.
- Takayama K., Taki W., Toma N. et al. Effect of Pitavastatin on Preventing Ischemic Complications with Carotid Artery Stenting: A Multicenter Prospective Study - EPOCH-CAS Study // Cardiovasc. Intervent. Radiol. - 2014; 37: 1436-43.
- Катапано А., Кухарчук В.В., Сергиенко И.В. и др. Питавастатин -современный статин для коррекции дислипидемии и риска сердечнососудистых осложнений. Резолюция экспертного совета // Атеросклероз и дислипидемии. - 2017; 2: 104-6.
Supplementary files
